標(biāo)題：Research Grade Abituzumab，AntibodySystem Laboratories
貨號(hào)：DHC21901
產(chǎn)品鏈接：http://www.antibodysystem.com/product/188.html
寄主物種：Human
形式：Liquid
存儲(chǔ)緩沖區(qū)：0.01M PBS, pH 7.4.
濃度：1 mg/ml
純度：>95% by SDS-PAGE.
克隆性：Monoclonal
應(yīng)用：Research Grade Biosimilar
介紹：Abituzumab是一種人源化抗 integrin αV 單克隆抗體 (IgG2 型)。Abituzumab 能有效減少 FAK、 Akt 和 ERK 的磷酸化。Abituzumab 可用于癌癥，尤其是前列腺癌的研究。
儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
參考文獻(xiàn)：
Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. PMID: 28314844
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. PMID: 33004536
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. PMID: 25319061
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID: 26839144
Integrins as A New Target for Cancer Treatment. PMID: 30451118
Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs. PMID: 37278511
Integrin Inhibitors in Prostate Cancer. PMID: 29415418
Integrins as Therapeutic Targets: Successes and Cancers. PMID: 28832494
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? PMID: 23838638
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. PMID: 29893938
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. PMID: 20031203
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. PMID: 24242902
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. PMID: 23791392
